Literature DB >> 31831640

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.

Keelan Z Guiley1,2, Jack W Stevenson2, Kevin Lou2, Krister J Barkovich2, Vishnu Kumarasamy3, Tilini U Wijeratne1, Katharine L Bunch1, Sarvind Tripathi1, Erik S Knudsen3, Agnieszka K Witkiewicz3, Kevan M Shokat2, Seth M Rubin4.   

Abstract

The p27 protein is a canonical negative regulator of cell proliferation and acts primarily by inhibiting cyclin-dependent kinases (CDKs). Under some circumstances, p27 is associated with active CDK4, but no mechanism for activation has been described. We found that p27, when phosphorylated by tyrosine kinases, allosterically activated CDK4 in complex with cyclin D1 (CDK4-CycD1). Structural and biochemical data revealed that binding of phosphorylated p27 (phosp27) to CDK4 altered the kinase adenosine triphosphate site to promote phosphorylation of the retinoblastoma tumor suppressor protein (Rb) and other substrates. Surprisingly, purified and endogenous phosp27-CDK4-CycD1 complexes were insensitive to the CDK4-targeting drug palbociclib. Palbociclib instead primarily targeted monomeric CDK4 and CDK6 (CDK4/6) in breast tumor cells. Our data characterize phosp27-CDK4-CycD1 as an active Rb kinase that is refractory to clinically relevant CDK4/6 inhibitors.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31831640      PMCID: PMC7592119          DOI: 10.1126/science.aaw2106

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  78 in total

1.  The CCP4 suite: programs for protein crystallography.

Authors: 
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-09-01

Review 2.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

3.  Incomplete folding upon binding mediates Cdk4/cyclin D complex activation by tyrosine phosphorylation of inhibitor p27 protein.

Authors:  Li Ou; Antonio M Ferreira; Steve Otieno; Limin Xiao; Donald Bashford; Richard W Kriwacki
Journal:  J Biol Chem       Date:  2011-06-29       Impact factor: 5.157

4.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

5.  Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.

Authors:  B A Schulman; D L Lindstrom; E Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

6.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

7.  Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.

Authors:  I Reynisdóttir; K Polyak; A Iavarone; J Massagué
Journal:  Genes Dev       Date:  1995-08-01       Impact factor: 11.361

8.  Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4.

Authors:  Michelle D Larrea; Jiyong Liang; Thiago Da Silva; Feng Hong; Shan H Shao; Kathy Han; D Dumont; Joyce M Slingerland
Journal:  Mol Cell Biol       Date:  2008-08-18       Impact factor: 4.272

Review 9.  Targeting CDK4 and CDK6: From Discovery to Therapy.

Authors:  Charles J Sherr; David Beach; Geoffrey I Shapiro
Journal:  Cancer Discov       Date:  2015-12-11       Impact factor: 39.397

10.  Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4.

Authors:  Priyank Patel; Benedikt Asbach; Elina Shteyn; Cindy Gomez; Alexander Coltoff; Sadia Bhuyan; Angela L Tyner; Ralf Wagner; Stacy W Blain
Journal:  Mol Cell Biol       Date:  2015-03-02       Impact factor: 5.069

View more
  43 in total

1.  CDK4/6 inhibitor palbociclib reduces inflammation in lupus-prone mice.

Authors:  Yongfeng Zhang; Ben Jin; Haiyan D Miller; Dongxia Ge; Xin Zhang; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

2.  INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.

Authors:  Qing Li; Baishan Jiang; Jiaye Guo; Hong Shao; Isabella S Del Priore; Qing Chang; Rei Kudo; Zhiqiang Li; Pedram Razavi; Bo Liu; Andrew S Boghossian; Matthew G Rees; Melissa M Ronan; Jennifer A Roth; Katherine A Donovan; Marta Palafox; Jorge S Reis-Filho; Elisa de Stanchina; Eric S Fischer; Neal Rosen; Violeta Serra; Andrew Koff; John D Chodera; Nathanael S Gray; Sarat Chandarlapaty
Journal:  Cancer Discov       Date:  2021-09-20       Impact factor: 38.272

Review 3.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

Review 4.  Cell cycle control in cancer.

Authors:  Helen K Matthews; Cosetta Bertoli; Robertus A M de Bruin
Journal:  Nat Rev Mol Cell Biol       Date:  2021-09-10       Impact factor: 94.444

Review 5.  Fluorescent kinase inhibitors as probes in cancer.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Chem Soc Rev       Date:  2021-07-22       Impact factor: 60.615

6.  Bipartite binding of the N terminus of Skp2 to cyclin A.

Authors:  Susan Kelso; Stephen Orlicky; Jonah Beenstock; Derek F Ceccarelli; Igor Kurinov; Gerald Gish; Frank Sicheri
Journal:  Structure       Date:  2021-05-13       Impact factor: 5.871

7.  PARP14 regulates cyclin D1 expression to promote cell-cycle progression.

Authors:  Michael J O'Connor; Tanay Thakar; Claudia M Nicolae; George-Lucian Moldovan
Journal:  Oncogene       Date:  2021-06-22       Impact factor: 9.867

8.  A cyclin D-CDK6 dimer helps to reshuffle cyclin-dependent kinase inhibitors (CKI) to overcome TGF-beta-mediated arrest and maintain CDK2 activity.

Authors:  Sarah E Nataraj; Stacy W Blain
Journal:  Cell Cycle       Date:  2021-04-02       Impact factor: 4.534

Review 9.  Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.

Authors:  Xiaoli Hu; Jing Wang; Man Chu; Yi Liu; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Ther       Date:  2021-01-01       Impact factor: 11.454

10.  Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.

Authors:  Lindsey R Pack; Leighton H Daigh; Mingyu Chung; Tobias Meyer
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.